Global Longevity Summit 2025: Spotlight on Dr. Steve Horvath, New Advisory Board Members, and Early Registration Opportunity
Informa Connect's Global Longevity Summit continues to break new ground in the science of aging and human performance with the announcement of its 2025 keynote speaker, new advisory board appointments, and a call to act before the upcoming ticket price increase.
GENEVA, SWITZERLAND, June 12, 2025 (GLOBE NEWSWIRE) -- Biogerontologist and epigenetic researcher Dr. Steve Horvath will headline the event as its keynote speaker and will be formally recognized as the recipient of the 2025 Global Longevity Award for his exceptional work in the development of the epigenetic clock - a breakthrough that continues to reshape our understanding of biological aging and predictive biomarkers.
The Global Longevity Summit convenes from October 28–30, 2025, at the Genolier Innovation Hub in Geneva, Switzerland. The event brings together a distinguished cohort of 300 global leaders across healthcare, science, business, and capital. Under this year's theme, 'Mastering the Aging Clock: The Science of Longevity,' the program will feature cutting-edge insight into epigenetics, regenerative medicine, AI-powered health optimization, and precision intervention strategies.
The Summit also expands its leadership circle with new Scientific and Professional Advisory Board members, each selected for their expertise in advancing healthy human lifespan. These new appointments reinforce the event's global vision and commitment to multidisciplinary innovation.
This year's event is shaping up to be the most anticipated yet - and with demand rising, early registration is strongly encouraged. Ticket prices will increase on July 1, and delegate spots are limited. Interested participants are urged to secure access now to avoid missing this landmark opportunity.
The Global Longevity Summit is an invitation-only event requiring participant approval. Qualified professionals and executives in the longevity ecosystem may apply to join at informaconnect.com/global-longevity-summit/.
About the Global Longevity SummitThe Global Longevity Summit is the definitive gathering of international leaders dedicated to advancing human longevity through scientific innovation and strategic collaboration. The invitation-only conference unites experts, entrepreneurs, and investors to accelerate breakthroughs in life extension and power the future of healthy aging.
CONTACT: Drew Wilson Global Longevity Summit (+1) 713-725-8983 drew.wilson@informa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th Presentation Ticker(s) Nika Pharmaceuticals (OTCQB: NIKA) Tivic Health Systems Inc. (NASDAQ: TIVC) Adia Nutrition, Inc. (OTCQB: ADIA) Sandoz Group AG (OTCQX: SDZNY | SIX: SDZ) June 12th Presentation Ticker(s) CSL Ltd. (OTCQX: CSLLY | ASX: CSL) Sharps Technology, Inc. (NASDAQ: STSS) Heidelberg Pharma AG (XETRA: HPHA) SBC Medical Group Holdings Incorporated (NASDAQ: SBC) Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) IMUNON, Inc. (NASDAQ: IMNN) Bio-Path Holdings, Inc. (OTCQB: BPTH) Perimeter Medical Imaging AI, Inc. (OTCQX: PYNKF | TSXV: PINK) MetaVia Inc. (NASDAQ: MTVA) Conavi Medical Corp. (OTCQB: CNVIF | TSXV: CNVI) Vycor Medical, Inc. (OTCQB: VYCO) Envoy Medical, Inc. (NASDAQ: COCH) Starpharma Holdings Ltd. (OTCQX: SPHRY | ASX: SPL) To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Media Contact:OTC Markets Group Inc. +1 (212) 896-4428, media@ Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@
Yahoo
2 hours ago
- Yahoo
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. This brings his total holding to 6,500,000 shares. About AccuStem AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor 'stemness,' we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit Investor and Media Contact:Wendy BlosserEmail: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy. The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL. Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include: Clinical Activity Observed: 9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction. 1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles. 1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing. 1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR. 2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient. Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use. Pharmacokinetics/Pharmacodynamics: FLT3 inhibition correlated with BMF-500 systemic exposures. Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration. Survival: Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation. For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation. These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1 Ongoing Dose Escalation: Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B). Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D'). Safety and Tolerability BMF-500 was generally well-tolerated across dose levels. No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported. Escalation is ongoing without safety restrictions. 'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.' Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program. Poster Presentation Details Date/Time: Saturday, June 14 (18:30-19:30 CEST) Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) Poster Number: PS1520 Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at using the identifier, NCT05918692. About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@
